

Supplementary Table 1. Univariate and multivariate analysis of the correlation between variables and pathologic EPE in favorable intermediate risk group

| Variable | No EPE (n=35) | EPE (n=15) | Univariate analysis | Multivariate analysis | p-value |
|---|---------------|------------|---------------------|------------------------|---------|
| | | | p-value | OR (95% CI) | |
| Age (yr) | 63.3±6.3 | 69.0±5.5 | 0.004 | 1.278 (1.083–1.508) | 0.004 |
| PSA (ng/mL) | 7.2±3.5 | 7.9±3.6 | 0.565 | - | - |
| PSA density (ng/mL ²) | 0.20±0.09 | 0.25±0.16 | 0.147 | - | - |
| Clinical ISUP on prostate needle biopsy | | | 0.792 | - | - |
| GGG1 | 8 (22.9) | 2 (13.3) | | - | - |
| GGG2 | 27 (77.1) | 13 (86.7) | | - | - |
| Maximum percentage of tumor length in a positive core (%) | 45.3±20.7 | 47.3±25.5 | 0.770 | - | - |
| Total positive core rate (%) | 22.6±11.0 | 22.8±10.3 | 0.970 | - | - |
| Clinical stage | | | 0.193 | - | - |
| T1c | 18 (51.4) | 5 (33.3) | | - | - |
| T2a | 15 (42.9) | 8 (53.3) | | - | - |
| T2b | 1 (2.9) | 2 (13.3) | | - | - |
| T2c | 1 (2.9) | 0 (0) | | - | - |
| Suspicious EPE on mpMRI | 3 (8.6) | 6 (40.0) | 0.015 | 21.178 (2.711–165.448) | 0.004 |

Values are presented as mean±standard deviation or number (%).

EPE, extraprostatic extension; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; ISUP, International Society of Urological Pathology; GGG, Gleason grade group; mpMRI, multiparametric magnetic resonance imaging.